BMX.WAR Biomaxima
- Market cap
- PLN 39.8M
- P/E
- 45.2x
- P/B
- 0.83x
- ROE
- 2.9%
- Dividend yield
- -
- Fundamental score
- 1.6/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is BMX.WAR undervalued?
Graham numberBMX.WAR trades 29.1% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Biomaxima fundamental analysis
7 of 22 checks passedROE 0/2
Low return on equity (2.9%), below 10%.
ROA 1/1
Return on assets (1.7%) is above the industry median (-18.6%).
Profit Consistency 2/2
Profitable for 6 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Last year's EPS growth (-80.4%) is not above the 5-year average (-57.7% a year).
Earnings Growth vs Industry 0/1
Last year's EPS growth (-80.4%) is below the industry median (2.6%).
Revenue Growth 0/2
Revenue shrank 24.9% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (34.5%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Debt Coverage 0/1
Operating cash flow does not cover 20% of total debt.
Interest Coverage 0/1
EBIT is negative, against interest expense, below 5x.
PE vs Market 0/1
PE (46.2x) is above the market median (11.6x).
PE vs Industry 0/1
PE (46.2x) is above the industry median (18.6x).
PBV 1/1
Price to book (0.8x) is below the industry median (3.6x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 39.1, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Biomaxima stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Biomaxima
BioMaxima S.A. produces and distributes microbiological media, reagents, and in vitro diagnostic equipment in Poland. It offers microbiology products, including ready to use media, such as plates, bottles, bags, and media in tubes; dehydrated media; agars and peptones; and supplements. The company also provides molecular biology and cell culture products which include real time PCR, nucleic acid isolation, NA and PCR electrophoresis, protein electrophoresis, enzymes, antibio…
Full company profileBiomaxima financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Biomaxima annual financial statements (PLN; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 27.0M | 31.6M | 30.8M | 30.5M | 61.6M | 79.1M | 144M | 46.8M | 52.9M | 60.9M | 55.8M |
| Gross Profit | 11.0M | 13.1M | 13.3M | 13.0M | 23.9M | 29.0M | 54.2M | 20.0M | 23.3M | 1.67M | 1.90M |
| Operating Income | 1.47M | 1.06M | -247K | 683K | 10.5M | 13.7M | 34.9M | 728K | 1.31M | -135K | -366K |
| EBITDA | 3.36M | 3.09M | 1.20M | 2.45M | 11.4M | 14.7M | 38.4M | 3.28M | 4.65M | 3.57M | 3.56M |
| Net Income | 1.23M | 806K | -482K | -13.5K | 7.95M | 10.2M | 28.9M | 586K | 535K | 105K | 1.38M |
| EPS | 0.33 | 0.22 | -0.13 | 0.00 | 1.85 | 2.29 | 6.48 | 0.14 | 0.13 | 0.03 | 0.33 |
| Balance Sheet | |||||||||||
| Total Assets | 23.4M | 27.3M | 44.0M | 43.3M | 53.4M | 61.9M | 74.4M | 73.8M | 76.3M | 77.5M | 79.7M |
| Total Liabilities | 6.58M | 9.93M | 27.1M | 26.8M | 27.5M | 32.7M | 22.0M | 26.8M | 29.0M | 23.8M | 31.4M |
| Shareholders' Equity | 16.8M | 17.3M | 16.8M | 16.4M | 19.9M | 29.2M | 52.5M | 47.0M | 47.3M | 48.1M | 48.3M |
| Cash & Short-term Investments | 767K | 1.36M | 1.03M | 506K | 4.39M | 3.01M | 12.9M | 1.50M | 909K | 1.74M | 1.20M |
| Total Debt | 3.69M | 5.00M | 15.8M | 12.1M | 12.4M | 17.3M | 5.83M | 12.9M | 14.6M | 14.5M | 16.7M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.44M | 1.84M | 2.12M | 4.93M | 3.97M | -132K | 37.1M | 1.59M | -152K | 2.34M | -4.62M |
| Capital Expenditure | 376K | 2.17M | 17.4M | 1.64M | 1.88M | 4.48M | 9.88M | 18.1M | 2.27M | 999K | 608K |
| Free Cash Flow | 1.06M | -328K | -15.3M | 3.29M | 2.09M | -4.61M | 27.2M | -16.5M | -2.42M | 1.34M | -5.23M |
| Ratios | |||||||||||
| ROE | 7.3% | 4.7% | -2.9% | -0.1% | 40.0% | 35.1% | 55.1% | 1.2% | 1.1% | 0.2% | 2.9% |
| ROA | 5.2% | 3.0% | -1.1% | 0.0% | 14.9% | 16.5% | 38.8% | 0.8% | 0.7% | 0.1% | 1.7% |
| Net Profit Margin | 4.5% | 2.6% | -1.6% | 0.0% | 12.9% | 13.0% | 20.1% | 1.3% | 1.0% | 0.2% | 2.5% |
| Debt to Equity | 0.22x | 0.29x | 0.94x | 0.74x | 0.63x | 0.59x | 0.11x | 0.27x | 0.31x | 0.30x | 0.34x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Biomaxima dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jun 16, 2023
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | PLN 2.10M | 0.49 | 357.8% |
| 2022 | PLN 1.95M | 0.44 | 6.7% |
| 2021 | PLN 1.10M | 0.24 | 10.7% |
| 2020 | PLN 1.10M | 0.26 | 13.8% |
| 2019 | PLN 1.10M | 0.29 | - |
| 2018 | PLN 1.10M | 0.29 | - |
| 2017 | PLN 391K | 0.10 | 48.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Biomaxima
- Insiders 34.41%
- Institutions 0.05%
- Public & others 65.54%
- Shares outstanding 4.19M
- Free float 3.77M
Biomaxima company profile
- Company name
- Biomaxima
- Ticker
- BMX.WAR
- ISIN
- PLBIOMX00015
- Exchange
- Warsaw Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 143
- Fiscal year end
- December
- Address
- ul. Vetterów 5, Lublin, Poland, 20-277
- Phone
- 48 81 440 83 71
- Website
- biomaxima.com
About Biomaxima
BioMaxima S.A. produces and distributes microbiological media, reagents, and in vitro diagnostic equipment in Poland. It offers microbiology products, including ready to use media, such as plates, bottles, bags, and media in tubes; dehydrated media; agars and peptones; and supplements. The company also provides molecular biology and cell culture products which include real time PCR, nucleic acid isolation, NA and PCR electrophoresis, protein electrophoresis, enzymes, antibiotics, agaroses and molecular biology media, media and buffers for in vitro cultures, phenotypic micromatrices, plastics and small equipment, basic substrate components, and form. In addition, it offers laboratory diagnostics solutions for various areas of clinical chemistry, haematology, coagulology, immunochemistry, POCT, rapid tests, and blood collection systems; and disposable materials comprising microbiology, dispensing equipment, tubes, plugs, tripods, capillaries, equipment, aspiration-vacuum system, containers, tank for analysers, urine analysis, microscope slides, reagent tubes, and autoclave equipment. BioMaxima S.A. was founded in 1997 and is headquartered in Lublin, Poland.
Biomaxima management
4- Mr. Lukasz UrbanPresident of the Management Board · born 1971
- Mr. Henryk LewczukCFO & Member of the Management Board
- Mr. Piotr JanowskiCOO & Member of the Management Board
- Zaneta HomendaChief Accounting Officer